bioRxiv preprint doi: https://doi.org/10.1101/2020.07.01.183202; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Muribaculaceae genomes assembled from metagenomes suggest genetic drivers of differential response to acarbose treatment in mice Byron J. Smitha,* Richard A. Millerb Thomas M. Schmidta,c,# aDepartment of Ecology & Evolutionary Biology, University of Michigan, Ann Arbor, MI, USA. bDepartment of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI, USA. cDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. *Present address: J. David Gladstone Institutes, San Francisco, CA, USA. #Correspondence:
[email protected] Running title: Genomes of acarbose-responsive Muribaculaceae Word Count: Abstract: 249 Importance: 149 Manuscript: 6,369 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.01.183202; this version posted December 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 2 Abstract The drug acarbose (ACA) is used to treat diabetes, and, by inhibiting α-amylase in the small intestine, increases the amount of starch entering the lower digestive tract. This results in changes to the composition of the microbiota and their fermentation products. Acarbose also increases longevity in mice, an effect that has been correlated with increased production of the short-chain fatty acids propionate and butyrate.